Similar articles

• May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol.

  Serra M, Pasello M, Manara MC, Scotlandi K, Ferrari S, Bertoni F, Mercuri M, Alvegard TA, Picci P, Bacci G, Smeland S. Serra M, et al. Int J Oncol. 2006 Dec;29(6):1459-68. Int J Oncol. 2006. PMID: 17088985 Clinical Trial.
• P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy.

  Baldini N, Scotlandi K, Serra M, Picci P, Bacci G, Sottili S, Campanacci M. Baldini N, et al. J Orthop Res. 1999 Sep;17(5):629-32. doi: 10.1002/jor.1100170502. J Orthop Res. 1999. PMID: 10569469
• Expression of the human multidrug resistance gene (MDR1) and prognostic correlation in human osteogenic sarcoma.

  Imanishi T, Abe Y, Suto R, Higaki S, Ueyama Y, Nakamura M, Tamaoki N, Fukuda H, Imai N. Imanishi T, et al. Tokai J Exp Clin Med. 1994 Sep;19(1-2):39-46. Tokai J Exp Clin Med. 1994. PMID: 7660382
• [Present status of the chemotherapy of malignant bone tumors].

  Yamawaki S. Yamawaki S. Nihon Seikeigeka Gakkai Zasshi. 1992 Jan;66(1):126-36. Nihon Seikeigeka Gakkai Zasshi. 1992. PMID: 1548438 Review. Japanese. No abstract available.
• Osteosarcoma in adolescents and young adults: new developments and controversies. The Mayo Clinic studies.

  Miser JS, Pritchard DJ, Rock MG, Shives TC, Gilchrist GS, Smithson WA, Arndt CA, Edmonson JH, Schaid DJ. Miser JS, et al. Cancer Treat Res. 1993;62:333-8. Cancer Treat Res. 1993. PMID: 8096748 Review. No abstract available.